Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets

v3.23.1
Intangible Assets
 3 Months Ended
Apr. 01, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

Note 7: Intangible Assets

Intangible assets as of April 1, 2023 and December 31, 2022 consist of the following (in $000’s):

 

 

 

April 1,
2023

 

 

December 31,
2022

 

Patent and domains

 

$

4

 

 

$

4

 

Soin intangibles *

 

$

19,293

 

 

$

19,293

 

Computer software

 

 

3,563

 

 

 

3,563

 

Intangible assets from discontinued operations

 

 

—

 

 

 

735

 

Intangible assets

 

 

22,860

 

 

 

23,595

 

Less accumulated amortization

 

 

(3,926

)

 

 

(3,563

)

Total intangible assets

 

$

18,934

 

 

$

20,032

 

 

*The Soin intangibles acquired by the Company consist of the following:

1.
Three pending patents related to the methods of using low-dose Naltrexone to treat chronic pain;
2.
Final formula for Naltrexone; and
3.
Orphan drug designation as approved by the FDA.

Intangible amortization expense from continuing operations was $363,000 and $0 for the 13 weeks ended April 1, 2023 and April 2, 2022.